BRCA Panel Plus

Test Code
92587


CPT Codes
81162, 81307, 81321, 81323, 81351, 81404, 81405, 81406, 81479

Preferred Specimen
5 mL whole blood collected in an EDTA (lavender-top) or ACD (yellow-top) tube


Patient Preparation
Saliva: Do not eat, drink, smoke or chew gum for 30 minutes before collection.

Buccal swab: Please refer to user instructions provided with kit. Ensure the sponge tip does not come into contact with any surface prior to collection. Do not eat, drink, smoke, or chew gum for 30 minutes before collection. Do not touch swab tips or allow contact with any other object.

Minimum Volume
2 mL whole blood • 2 mL saliva • 1 buccal swab • 10 mg skin fibroblasts • 2 flasks 75% confluent


Other Acceptable Specimens
2 mL saliva to "fill to" line collected in OGD-500, Oragene-Dx Collection Kit or
1 buccal swab submitted in OCD-100A buccal kit (ORAcollect-Dx Collection Kit) or
10 mg skin fibroblasts collected in sterile plastic container or
2 flasks skin fibroblasts collected in each of two separate sterile T25 culture flasks or equivalent with 80-100% confluent growth


Instructions
Do not hold specimen. Forward to laboratory when specimen arrives.

Whole blood: Normal phlebotomy procedure. Specimen stability is crucial. Store and ship room temperature immediately. Do not freeze.

Saliva: 2 mL saliva collected in the Oragene-Dx collection kit up to the "fill to" line (OGD-500/OGD-600, OGD-510/OGD-610). Do not remove the plastic film from the funnel lid.

For fibroblasts and skin fibroblasts, call 1-866-GENEINFO (1-866-436-3463) prior to collecting and ordering.


Transport Temperature
Room temperature


Specimen Stability

Whole blood
Room temperature: 14 days
Refrigerated: 14 days
Frozen: Unacceptable

Saliva or buccal swab
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 14 days

Fibroblasts and skin fibroblasts
Room temperature: 48 hours
Refrigerated: Unacceptable
Frozen: Unacceptable



Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Do not reject


Methodology
DNA Bait Capture • Long Range Polymerase Chain Reaction • Next Generation Sequencing • Microarray

FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Setup Schedule
Sets up 3 days a week.


Clinical Significance
Approximately 5-10% of breast cancer cases are hereditary. BRCA1 and BRCA2 account for 15-20% of hereditary breast cancers. Five additional breast cancer susceptibility genes include CDH1, PALB2, PTEN, STK11 and TP53. Sequence analysis and deletion/duplication analysis of these five genes can explain an additional 3% to 4.5% of hereditary breast cancers.




The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.